Trial reportDrug design, development and therapy2025
Comparison of Remimazolam versus Dexmedetomidine on Hemodynamics in Older Patients Under Lower Extremity Orthopedic Surgery with Spinal Anesthesia: A Randomized Controlled Trial.
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The impact of remimazolam on postoperative neurocognitive disorder in elderly surgical patients: a systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Efficacy and safety of combined supra-inguinal fascia iliaca compartment block and sacral plexus block versus spinal anesthesia in elderly patients undergoing hip fracture surgery: a prospective randomized controlled trial.Journal of orthopaedic surgery and research · 2026Trial
- Patient-Controlled Sedation with Remimazolam Enables More Precise Intraoperative Sedation in Elderly Patients Under Spinal Anesthesia: A Randomized Controlled Trial.Drug design, development and therapy · 2026Trial
- Interpretable machine learning for postoperative nausea and vomiting prediction in elderly orthopedic patients: a comparative study.BMC medical informatics and decision making · 2026Article
- Discontinuation of the development of remimazolam for ICU sedation in Japan: background and rationale.Journal of intensive care · 2026Review
- Hypotension incidence comparison between remimazolam and propofol in hypertensive patients undergoing spinal surgery.American journal of translational research · 2026Article
- Rapid quantification and validation of etomidate and dexmedetomidine blood concentrations in rats using a novel portable mass spectrometer.Frontiers in veterinary science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To compare the effects of remimazolam and dexmedetomidine on the hemodynamics in elderly patients undergoing orthopedic surgery under spinal anesthesia. Methods: This study evaluated 126 patients aged ≥ 60 years undergoing lower-extremity orthopedic surgery under spinal anesthesia, randomizing them into remimazolam and dexmedetomidine groups. The primary outcome was the incidence of hemodynamic fluctuations, such as hypotension and bradycardia. The secondary endpoints included the cumulative dose vasoactive medication and the incidence of hypertension, tachycardia, postoperative nausea and vomiting (PONV), postoperative delirium (POD), and hypoxemia. Continuous hemodynamic variables including mean arterial pressure (MAP) and heart rate (HR) were recorded at baseline, every 5 min for the first 20 min after intravenous infusion of sedatives, every 10 min thereafter, up to one hour, at the end of the surgery, and in the post-anesthesia care unit (PACU). Results: Compared to dexmedetomidine group, patients in the remimazolam group demonstrated significantly higher MAP at three specific time points (60 minutes after baseline, at the end of surgery, and in the PACU) and higher HR at all time points after T3 (15 minutes after baseline). The remimazolam group also reduced norepinephrine and atropine interventions. There were no statistically significant differences in other adverse events between the two groups. Conclusion: Remimazolam demonstrated superior hemodynamic stability and fewer adverse cardiovascular events than dexmedetomidine, along with reduced requirements for vasoactive medications, making it an alternative to intraoperative sedation in older patients undergoing lower limb surgery under spinal anesthesia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.